Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are an important component of antiretroviral therapy for HIV type-1 (HIV-1)-infected patients. Development of NNRTI resistance can lead to treatment failure and is conferred by the presence of specific resistance-associated mutations (RAMs) in the reverse transcriptase. In addition to the widely used list of NNRTI RAMs provided by the International AIDS Society-USA HIV-1 Drug Resistance Mutation Group, which were identified on the basis of clinical experience with the approved NNRTIs, a more comprehensive list of NNRTI RAMs is needed to guide the study of baseline and emerging resistance to new NNRTIs.
Methods
We conducted an extensive review of the existing literature on NNRTI resistance, together with several in vitro and in vivo studies on the mechanism of HIV-1 resistance to approved NNRTIs and to NNRTIs formerly or currently in clinical development.
Results
In total, 44 NNRTI RAMs were identified. These included V90I, A98G, L100I, K101E/P/Q, K103H/N/S/T, V106A/I/M, V108I, E138G/K/Q, V179D/E/F/G/I, Y181C/ I/V, Y188C/H/L, V189I, G190A/C/E/Q/S, H221Y, P225H, F227C/L, M230I/L, P236L, K238N/T and Y318F. These NNRTI RAMs were observed, either alone or in combination with others, ranging in frequency from 0.02% to 56.96% in a panel of 101,679 NNRTI-resistant isolates submitted to Virco BVBA (Mechelen, Belgium) for routine clinical resistance testing. Phenotypical data from site-directed mutants helped to establish the contribution of each mutation to NNRTI resistance.
Conclusions
The list of 44 NNRTI RAMs compiled in this study provides a comprehensive overview of mutations that play a role in HIV-1 NNRTI resistance and can be used to guide further in vitro and in vivo research on the mechanisms of HIV-1 NNRTI resistance.
References
1.
GotteM., LiX., WainbergM.A.HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction.Arch Biochem Biophys1999; 365: 199–210.
2.
TelesnitskyA., GoffS.P.Reverse transcriptase and the generation of retroviral DNA. In CoffinJ.M., HughesS.H., VarmusH.E. (Editors). Retroviruses.New York: Cold Spring Harbor Laboratory Press1997. pp. 121–160.
3.
De ClercqE.Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.Chem Biodivers2004; 1: 44–64.
VingerhoetsJ., AzijnH., FransenE.TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.J Virol2005; 79: 12773–12782.
RinehartA.R., LecocqP., McKennaP., PatteryT., WasikowskiB., BachelerL.T.Predicted phenotypic resistance in routine clinical samples between 1998 and 2003.Antivir Ther2004; 9: S90.
9.
LittleS.J., HolteS., RoutyJ.P.Antiretroviral drug resistance among patients recently infected with HIV.N Engl J Med2002; 347: 385–394.
10.
WensingA.M., BoucherC.A.Worldwide transmission of drug-resistant HIV.AIDS Rev2003; 5: 140–155.
11.
JohnsonV.A., Brun-VézinetF., ClotetB.Update of the drug resistance mutations in HIV-1: 2007.Top HIV Med2007; 15: 119–125.
12.
JohnsonV.A., Brun-VézinetF., ClotetB.Update of the drug resistance mutations in HIV-1: Spring 2008.Top HIV Med2008; 16: 62–68.
13.
ParkinN.T., GuptaS., ChappeyC., PetropoulosC.J.The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to non-nucleoside reverse transcriptase inhibitors.Antimicrob Agents Chemother2006; 50: 351–354.
14.
HarriganP.R., MoT., WynhovenB.Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors.AIDS2005; 19: 549–554.
15.
PelemansH., AertsenA., Van LaethemK.Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.Virology2001; 280: 97–106.
16.
The Stanford University HIV Drug Resistance Database.NNRTI resistance notes: NNRTI resistance matrix. (Updated 25 September 2007. Accessed 1 February 2008.) Available from http://hivdb.stanford.edu/cgi-bin/NNRTIResiNote.cgi.
17.
VermeirenH., Van CraenenbroeckE., AlenP.Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.J Virol Methods2007; 145: 47–55.
18.
ClarkS., CalefC., MellorsJ.Mutations in retroviral genes associated with drug resistance. In LeitnerT., FoleyB., HahnB. (Editors). HIV Sequence Compendium 2006/2007.New Mexico: Theoretical Biology and Biophysics Group2007. pp. 58–158.
19.
VingerhoetsJ., BuelensA., PeetersM.Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2.Antivir Ther2007; 12 Suppl 1: S34.
20.
ByrnesV.W., SardanaV.V., SchleifW.A.Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors.Antimicrob Agents Chemother1993; 37: 1576–1579.
21.
BachelerL.T., AntonE.D., KudishP.Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.Antimicrob Agents Chemother2000; 44: 2475–2484.
22.
MellorsJ.W., ImG.J., TramontanoE.A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl) imidazo[4,5,1-jk] [1,4] benzodiazepin-2(1H)-thione (TIBO R82150).Mol Pharmacol1993; 43: 11–16.
23.
RheeS-Y, LiuT., RavelaJ., GonzalesM.J., ShaferR.W.Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing.Antimicrob Agents Chemother2004; 48: 3122–3126.
24.
KleimJ-P, WintersM., DunklerA.Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study.J Infect Dis1999; 179: 709–713.
25.
Ceccherini-SilbersteinF., SvicherV., SingT.Characterization and structural analysis of novel mutations in HIV-1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.J Virol2007; 81: 11507–11519.
26.
NunbergJ.H., SchlelfW.A., BootsE.J.Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.J Virol1991; 65: 4887–4892.
27.
LarderB.A.3’-Azido-3’-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.Antimicrob Agents Chemother1992; 36: 2664–2669.
28.
KleimJ.P., WinklerI., RösnerM.In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097.Virology1997; 231: 112–118.
29.
TaylorD.L., AhmedP.S., TymsA.S.Drug resistance and drug combination features of the human immunodeficiency virus inhibitor BCH-10652 [(+/-)-2’-deoxy-3’-oxa-4’-thiocytidine, dOTC].Antivir Chem Chemother2000; 11: 291–301.
30.
LoembaH., BrennerB., ParniakM.A.Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against non-nucleoside inhibitors of RT.Antimicrob Agents Chemother2002; 46: 2087–2094.
31.
BalzariniJ., KarlssonA., SardanaV.V., EminiE.A., CamarasaM.J., De ClercqE.Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K) RT HIV-1 mutants or select for highly resistant (Y181C– >C181I) RT HIV-1 mutants.Proc Natl Acad Sci U S A1994; 91: 6599–6603.
32.
McCreedyB., Borroto-EsodaK., HarrisJ., KlishC., FangL., MirallesD.Genotypic and phenotypic analysis of HIV-1 from patients receiving combination therapy containing two nucleoside reverse transcriptase inhibitors (NRTIs) and the non-NRTI, emivirine (MKC-442).Antivir Ther1999; 4 Suppl 1: 9.
33.
PalmerP., DamE., FerchalF.V106M and V179D, a novel HIV-1 reverse transcriptase (RT) combination of mutations conferring high-level resistance to non-nucleoside RT inhibitors.Antivir Ther2003; 8 Suppl 1: S411–S412.
34.
VingerhoetsJ., PeetersM., CorbettC.Effect of baseline resistance on the virologic response to a novel NNRTI, TMC125, in patients with extensive NNRTI and PI resistance: analysis of study TMC125-223.13th Conference on Retroviruses and Opportunistic Infections. 5–8 February 2006, Denver, CO, USA. Abstract 154.
35.
MillerM.D., MargotN.A., McCollD.J.Characterization of resistance mutation patterns emerging over 2 years during first-line antiretroviral treatment with tenofovir DF or stavudine in combination with lamivudine and efavirenz.12th International Drug Resistance Workshop. 10–14 June 2003, Cabo del Sol, Los Cabos, Mexico. Abstract 135.
36.
TurnerD., BrennerB., MoisiD.Nucleotide and amino acid polymorphisms at drug resistanz ce sites in non-B-subtype variants of human immunodeficiency virus type 1.Antimicrob Agents Chemother2004; 48: 2993–2998.
37.
ShihC.K., RoseJ.M., HansenG.L.Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors.Proc Natl Acad Sci U S A1991; 88: 9878–9882.
38.
RichmanD.D.Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents.Antimicrob Agents Chemother1993; 37: 1207–1213.
39.
SardanaV.V., EminiE.A., GotlibL.Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors.J Biol Chem1992; 267: 17526–17530.
40.
KleimJ.P., RösnerM., WinklerI.Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74–>Val or Ile and Val-75–>Leu or Ile) HIV-1 mutants.Proc Natl Acad Sci U S A1996; 93: 34–38.
41.
BacollaA., ShihC.K., RoseJ.M.Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs.J Biol Chem1993; 268: 16571–16577.
42.
HuangW., GamarnikA., LimoliK., PetropoulosC.J., WhitcombJ.M.Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.J Virol2003; 77: 1512–1523.
43.
KleimJ-P, BenderR., BillhardtU-M. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication.Antimicrob Agents Chemother1993; 37: 1659–1664.
44.
KleimJ.P., BenderR., KirschR., MeichsnerC., PaessensA., RiebG.Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.Virology1994; 200: 696–701.
45.
GonzalesM.J., WuT.D., TaylorJ.Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.AIDS2003; 17: 791–799.
46.
SaracinoA., MonnoL., ScudellerL.Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.J Med Virol2006; 78: 9–17.
47.
PernoC.F., SvicherV., Ceccherini-SilbersteinF.Novel drug resistance mutations in HIV: recognition and clinical relevance.AIDS Rev2006; 8: 179–190.
48.
AndriesK., AzijnH., ThielemansT.TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.Antimicrob Agents Chemother2004; 48: 4680–4686.
49.
ParkinN.T., DeeksS.G., WrinM.T.Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients.AIDS2000; 14: 2877–2887.
50.
DuewekeT.J., PushkarskayaT., PoppeS.M.A mutation in reverse transcriptase of bis (heteroaryl) piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.Proc Natl Acad Sci U S A1993; 90: 4713–4717.
51.
DemeterL.M., MeehanP.M., MorseG.Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.J Acquir Immune Defic Syndr Hum Retrovirol1998; 19: 135–144.
52.
PelemansH., EsnoufR.M., JonckheereH., De ClercqE., BalzariniJ.Mutational analysis of tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.J Biol Chem1998; 273: 34234–34239.
53.
HarriganP.R., SalimM., StammersD.K.A mutation in the 3’ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.J Virol2002; 76: 6836–6840.
54.
JanssenP.A.J., LewiP.J., ArnoldE.In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).J Med Chem2005; 48: 1901–1909.
55.
BonneauP., RobinsonP., DuanJ.Antiviral characterization and human experience with BILR 355 BS, a novel next-generation non-nucleoside reverse transcriptase inhibitor with a broad anti HIV-1 profile.12th Conference on Retroviruses and Opportunistic Infections. 22–25 February 2005, Boston, MA, USA. Abstract 558.
56.
HamatakeR., ZhangZ., XuW.RDEA806, a potent NNRTI with a high genetic barrier to resistance.47th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17–20 September 2007, Chicago, IL, USA. Abstract 1662.
57.
GuptaS., FransenS., PaxinosE.Infrequent occurrence of mutations in the C-terminal region of reverse transcriptase modulates susceptibility to RT inhibitors.Antivir Ther2006; 11 Suppl 1: S143.
58.
YapS.H., SheenC.W., FaheyJ.N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.PLoS Med2007; 4: e335.
59.
HachiyaA., KodamaE.N., SarafianosS.G.Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors.J Virol2008; 82: 3261–3270.
60.
KearnyM., PalmerS., MaldarelliF.Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase.AIDS2008; 22: 497–501.
